^
    Back
    Association details:
    Biomarker:JAK1 S646F
    Cancer:Acute Lymphocytic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Blood
    Title:

    Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

    Excerpt:
    Xenograft V, which harbors a JAK1 S646F mutation without CRLF2 rearrangement (JAK1m/CRLF2NR), responded to ruxolitinib with lower peripheral and splenic blast counts compared with vehicle.
    DOI:
    https://dx.doi.org/10.1182%2Fblood-2012-03-415448